WO1994029277A1 - AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS - Google Patents

AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS Download PDF

Info

Publication number
WO1994029277A1
WO1994029277A1 PCT/EP1994/001921 EP9401921W WO9429277A1 WO 1994029277 A1 WO1994029277 A1 WO 1994029277A1 EP 9401921 W EP9401921 W EP 9401921W WO 9429277 A1 WO9429277 A1 WO 9429277A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclobutene
dione
amino
anilino
pyridyl
Prior art date
Application number
PCT/EP1994/001921
Other languages
French (fr)
Inventor
William John Coates
Derek Anthony Rawlings
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of WO1994029277A1 publication Critical patent/WO1994029277A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Definitions

  • the present invention relates to dioxocyclobutene derivatives, processes for their preparation, intermediates in their preparation, their use as therapeutic agents and to pharmaceutical compositions containing them.
  • the compounds of this invention are inhibitors of a calmodulin insensitive cyclic GMP phosphodiesterase and are of use in combating such conditions where such inhibition is thought to be beneficial. They are bronchodilators and are therefore of use in combating chronic reversible obstructive lung diseases such as asthma and bronchitis. Some of the compounds of the present invention have anti-allergic activity and are therefore useful in combating allergic diseases such as allergic asthma, allergic rhinitis, urticaria and gastrointestinal motility disorders such as irritable bowel syndrome.
  • the compounds of this invention are vasodilators and are therefore of value in combating angina, hypertension and congestive heart failure. Also the compounds of this invention are smooth muscle relaxants and are therefore of value in treating male sexual dysfunction, e.g. impotence.
  • Ar is an optionally substituted aryl or heteroaiyl ring selected from phenyl, naphthyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, imidazolyl, thienyl, oxazolyl, benzimidazolyl, benzoxazolyl, indolyl or thianaphthenyl, X is CH or N;
  • R ⁇ is NR J R2 or hydrogen; and R 1 and R- ⁇ are independently hydrogen or C1.5aU.-yl.
  • Ar is phenyl.
  • Ar is 2- ,3- or 4-pyridyl, 5-pyrimidyl, 2- or 4-imidazolyl, 2- or 3-thienyl, 2-oxazolyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-indolyl or 2-thianaphthenyl.
  • Preferred heteroaryl rings include 3-pyridyl, 2-thiophenyl or 2-indolyl
  • Ar is unsubstituted or substituted by at least one group selected from C ⁇ _6alkyl, C- ⁇ alkoxy or hydroxy.
  • Ar is positioned ortho- or meta- to X.
  • X is CH.
  • R° is NR ⁇ R 2 .
  • R* is hydrogen and R 2 is hydrogen or Ci.galkyl.
  • R 1 and R 2 are both hydrogen.
  • Examples of C ⁇ _6alkyl groups include methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably methyl.
  • Particular compounds of this invention include :
  • Compounds of the formula (1) may form pharmaceutically acceptable salts with acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acids.
  • Compounds of the formula (1) may form pharmaceuticaUy acceptable salts with metal ions, such as alkali metals for example sodium and potassium, or with an ammonium ion.
  • metal ions such as alkali metals for example sodium and potassium, or with an ammonium ion.
  • a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof for the treatment of humans and other mammals it is normaUy formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • Compounds of formula (1) and their pharmaceuticaUy acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, parenteraUy, transdermally, rectaUy, via inhalation or via buccal administration.
  • Compounds of formula (1) and their pharmaceutically acceptable salts which are active when given oraUy or via buccal administration can be formulated as Uquids, syrups, tablets, capsules and lozenges.
  • An oral Uquid formulation wiU generally consist of a suspension or solution of the compound or salt in a Uquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
  • a Uquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include starch, ceUuloses, lactose, sucrose and magnesium stearate.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule sheU.
  • composition is in the form of a soft gelatin sheU capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, ceUuloses, silicates or oUs and are incorporated in a soft gelatin capsule sheU.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenteraUy acceptable oil, for example polyethylene glycol, polyvinyl-pyrroUdone, lecithin, arachis oU, or sesame oU.
  • a typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats.
  • Typical transdermal formulations comprise a conventional aqueous or non- aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propeUant such as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
  • a conventional propeUant such as dichlorodifluoromethane or trichlorofluoromethane
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
  • Each dosage unit for oral administration contains suitably from 0.001 mg Kg to
  • each dosage unit for parenteral administration contains suitably from 0.001 mg/Kg to 10 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daUy dosage regimen for oral administration is suitably about 0.001 mg/Kg to 120 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daUy dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, for example about 0.005 mg/Kg to 10 mg/Kg, of a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof calculated as the free base.
  • the active ingredient may be administered as required for example from 1 to 8 times a day or by infusion.
  • the compositions of the invention are bronchodilators and are useful in chronic reversible obstructive lung disease for example asthma and bronchitis.
  • some of the compositions of the present invention have anti- aUergic activity and are useful in combating allergic diseases such as aUergic asthma, aUergic rhinitis, urticaria and irritable bowel syndrome.
  • the compositions of the present invention also have vasodilator activity and are of use in the treatment of angina, hypertension and congestive heart failure. Such conditions can be treated by administration oraUy, topically, rectally, parenteraUy or by inhalation.
  • inhalation dosages are controUed by a valve, are administered as required and for an adult are conveniently in the range 0.1-5.0 mg of a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof.
  • the compounds of this invention may be co-administered with other pharmaceuticaUy active compounds, for example in combination, concurrently or sequentiaUy.
  • the compounds of this invention and the other active compound or compounds are formulated in a pharmaceutical composition.
  • bronchodilators such as sympathomimetic amines for example isoprenaline, isoetharine, sulbutamol, phenylephrine and ephedrine or xanthine derivatives for example theophylline and aminophyUine, anti-aUergic agents for example disodium cromoglycate, histamine Hj-antagonists, vasodilators for example hydralazine, angiotensin converting enzyme inhibitors for example captopril, anti-anginal agents for example isosorbide nitrate, glyceryl trinitrate and pentaerythritol tetranitrate, anti-arrhythmic agents for example quinidine, procainamide and Ugnocaine, calcium antagonists for example verapamil and nifedipine, diuretics such as thiazides and related compounds for example bendrofluazide
  • the present invention provides a process for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of the formula (2) :
  • I-.* is C ⁇ _5alkoxy, halo or C ⁇ _6alkylthio, for examples methoxy, ethoxy, propoxy or n-butoxy.
  • the reaction may be performed in the absence of a solvent or in a solvent such as a C ⁇ _4alkanol (e.g. methanol or ethanol), acetonitrile or pyridine at ambient or elevated temperature such as 30 to 160°C, conveniently at reflux temperature when in the presence of a solvent.
  • a solvent such as a C ⁇ _4alkanol (e.g. methanol or ethanol), acetonitrile or pyridine
  • ambient or elevated temperature such as 30 to 160°C, conveniently at reflux temperature when in the presence of a solvent.
  • a compound of the formula (2) may be prepared by reacting in the presence of a paUadium catalyst a compound of the formula (4) with a compound of the formula (5) :
  • a suitable leaving group for ] or 1? is halo, preferably bromo or trifluoromethanesulphonate.
  • l_? is B(OH)2-
  • the reaction of a compound of the formula (4) with a compound of the formula (5) is performed in the presence of a base such as triethylamine, barium hydroxide, sodium carbonate or sodium bicarbonate, and when L-2 or l > is trifluoromethanesulphonate in the presence of Uthium chloride, in a solvent such as dimethoxyethane, tetrahydrofuran, benzene, ethanol, water or mixtures thereof, at elevated temperature (e.g. 30-150°C) preferably at the reflux temperature of the reaction mixture.
  • a base such as triethylamine, barium hydroxide, sodium carbonate or sodium bicarbonate
  • L-2 or l > is trifluoromethanesulphonate in the presence of Uthium chloride
  • a solvent such as dime
  • An example of a precursor of an amino group is a nitro group which can be reduced to an amino group in conventional manner, e.g. by catalytic hydrogenation.
  • An alternative precursor is a protected amino group such as phthalamido which can be deprotected in conventional manner.
  • An example of a precursor of the group Ar is when Ar is substituted by an optionaUy substituted benzyloxy group such as 4-methoxybenzyloxy which can be converted to Ar substituted by hydroxy in conventional manner, e.g. by catalytic hydrogenation.
  • an optionaUy substituted benzyloxy group such as 4-methoxybenzyloxy which can be converted to Ar substituted by hydroxy in conventional manner, e.g. by catalytic hydrogenation.
  • Pharmaceutically acceptable acid addition salts of the compounds of the formula (1) may be prepared from the corresponding base of the compounds of the formula (1) in conventional manner.
  • the base may be reacted with an acid in a C ⁇ 4alkanol, or an ion-exchange resin may be used.
  • the salts of the compounds of the formula (1) may be inter converted using ion-exchange resins.
  • Non-pharmaceuticaUy acceptable salts are therefore of use as they can be converted to pharmaceuticaUy acceptable salts.
  • Pharmaceutically acceptable base addition salts of the compounds of the formula (1) may be prepared by standard methods, for example by reacting a solution of the compound of the formula (1) with a solution of the base.
  • mice Male Duncan Hartley guinea-pigs (250-300 g) are sensitised to ovalbumen by i.p. injection of 2 ml of 50 mg.ml"! i.p. and 0.2 ml s.c. Three weeks later they are anaesthetised with 60 mg.kg'l sodium pentabarbitone.
  • the trachea is cannulated and the animal respires at a rate of 40 breaths per minute and at an initial tracheal inflation pressure of 16 mmHg. Tracheal inflation pressure is measured by a transducer connected to a side arm of the respiration circuit
  • the carotid artery is cannulated for the measurement of blood pressure and the signal is used to trigger an instantaneous rate meter.
  • the activity of the compounds of the present invention as inhibitors of a calmodulin insensitive cycUc GMP phosphodiesterase is measured using the procedure described in European Patent Application No.293063.
  • the concentration of compound which inhibits the enzyme by 50% is given as the IC50 ( ⁇ M).
  • the compounds of Examples 2, 5 to 11, 13 to 16, 18, 20 and 23 had IC50 values in the range 6 to 110 ⁇ M.
  • Segments of isolated guinea-pig colon (2 cm) are suspended under 2 g tension in standard organ baths containing Krebs solution.
  • the tissues are connected at the free end to isometric transducers which allow recording and display of developed tension on chart recorders.
  • On-line computer capture and analysis are used to quantify the effects of test compounds on spontaneous contractions. Inhibitory responses are calculated as % maximum inhibition of spontaneous contraction distance over 3 consecutive pre and post dose 2 minute readings. The concentration of compound which causes 50% inhibition of the spontaneous contraction is given as the EC50 ( ⁇ M).
  • Example 24 Pharmaceutical compositions for oral administration are prepared by combining the foUowing :
  • a pharmaceutical composition for parenteral administration is prepared by dissolving die title compound of Example 2 (0.02 g) in polyethylene glycol 300 (25 ml) with heating. This solution is then dUuted with water for injections Ph. Eur. (to 100 ml). The solution is tiien sterilised by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Abstract

A compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein Ar is an optionally substituted aryl or heteroaryl ring selected from phenyl, naphthyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, imidazolyl, thienyl, oxazolyl, benzimidazolyl, benzoxazolyl, indolyl or thianaphthenyl, X is CH or N; R?0 is NR1R2¿ or hydrogen; and R?1 and R2¿ are independently hydrogen or C¿1-6?alkyl. The compounds of this invention are inhibitors of calmodulin insensitive cyclic GMP phosphodiesterase and are of use in combating such conditions where such inhibition is thought to be beneficial.

Description

A 1 l 1 no- or pyrldyl ami no- cycl obutene- 1 , 2-dlone derivatives as cGMP phosphodl esterase I nhibi tors
The present invention relates to dioxocyclobutene derivatives, processes for their preparation, intermediates in their preparation, their use as therapeutic agents and to pharmaceutical compositions containing them. The compounds of this invention are inhibitors of a calmodulin insensitive cyclic GMP phosphodiesterase and are of use in combating such conditions where such inhibition is thought to be beneficial. They are bronchodilators and are therefore of use in combating chronic reversible obstructive lung diseases such as asthma and bronchitis. Some of the compounds of the present invention have anti-allergic activity and are therefore useful in combating allergic diseases such as allergic asthma, allergic rhinitis, urticaria and gastrointestinal motility disorders such as irritable bowel syndrome. Furthermore the compounds of this invention are vasodilators and are therefore of value in combating angina, hypertension and congestive heart failure. Also the compounds of this invention are smooth muscle relaxants and are therefore of value in treating male sexual dysfunction, e.g. impotence.
Accordingly the present invention provides compounds of the formula (1) :
Figure imgf000003_0001
Formula (1)
and pharmaceutically acceptable salts thereof, wherein
Ar is an optionally substituted aryl or heteroaiyl ring selected from phenyl, naphthyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, imidazolyl, thienyl, oxazolyl, benzimidazolyl, benzoxazolyl, indolyl or thianaphthenyl, X is CH or N;
Rθ is NRJR2 or hydrogen; and R1 and R-^ are independently hydrogen or C1.5aU.-yl. Suitably Ar is phenyl.
Suitably Ar is 2- ,3- or 4-pyridyl, 5-pyrimidyl, 2- or 4-imidazolyl, 2- or 3-thienyl, 2-oxazolyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-indolyl or 2-thianaphthenyl. Preferred heteroaryl rings include 3-pyridyl, 2-thiophenyl or 2-indolyl Suitably Ar is unsubstituted or substituted by at least one group selected from Cι_6alkyl, C-^alkoxy or hydroxy.
Suitably Ar is positioned ortho- or meta- to X. Suitably X is CH. Suitably R° is NRΪR2.
Suitably R* is hydrogen and R2 is hydrogen or Ci.galkyl. Preferably R1 and R2 are both hydrogen. Examples of Cι_6alkyl groups include methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably methyl.
Particular compounds of this invention include :
3-amino-4-[4-(3-pyridyl)]a-nilino-3-cyclobutene-l,2-dione,
3-ammc-4-[3-(4-imidazolyl)anilino]-3-cyclobutene- 1 ,2-dione, 3-methylamino-4- [3-(5-methyl-4-imidazolyl)anilino] -3-cyclobutene- 1 ,2-dione,
3-dimeΛylam o-4-[3-(5-memyl-4- ώdazolyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(3-methyl-4-pyridyl)anilino]-3-cyclobutene- 1 ,2-dione,
3-amino-4-[3-(2-oxazolyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(4-pyridyl)anilino]-3-cyclobutene-l,2-dione, 3-aιr no-4-[3-(3-pyridyl)anilino]-3-cyclobutene- 1 ,2-dione,
3-amino-4-[3-(2-pyridyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(2-thienyl)anilino]-3-cyclobutene- 1 ,2-dione,
3-a-tmno-4-[3-(3-tMenyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(2-thianaphthene)anilino]-3-cyclobutene-l,2-dione, 3-ammo-4-[3-(5-pyrimidyl)anilino]-3-cyclobutene-l,2-dione,
3-aminc-4-[3-(2-benz»xazoyl)anilino]-3-cyclobutene-l,2-dione,
3-aιnino-4-[3-(2-benzimidazolyl)anilino]-3-cyclobutene-l,2-dione,
3-ammo-4-[3-(2-indolyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-(3-phenyl)anilino-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(2-hydroxyphenyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(2-methoxyphenyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[3-(3-hydroxy-2-pyridyl)anilino]-3-cyclobutene-l,2-dione,
3-am o-4-[3-(2-imidazolyl)anilino]-3-cyclobutene-l,2-dione,
3-amino-4-[6-(4-pyridyl)-2-pyridylamino]-3-cyclobutene- 1,2-dione, and 3-[3-(4-pyridyl)anilino]-3-cyclobutene-l,2-dione, or pharmaceutically acceptable salts thereof.
Compounds of the formula (1) may form pharmaceutically acceptable salts with acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acids.
Compounds of the formula (1) may form pharmaceuticaUy acceptable salts with metal ions, such as alkali metals for example sodium and potassium, or with an ammonium ion.
In order to use a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof for the treatment of humans and other mammals it is normaUy formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Compounds of formula (1) and their pharmaceuticaUy acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, parenteraUy, transdermally, rectaUy, via inhalation or via buccal administration.
Compounds of formula (1) and their pharmaceutically acceptable salts which are active when given oraUy or via buccal administration can be formulated as Uquids, syrups, tablets, capsules and lozenges. An oral Uquid formulation wiU generally consist of a suspension or solution of the compound or salt in a Uquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include starch, ceUuloses, lactose, sucrose and magnesium stearate. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule sheU. Where the composition is in the form of a soft gelatin sheU capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, ceUuloses, silicates or oUs and are incorporated in a soft gelatin capsule sheU.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenteraUy acceptable oil, for example polyethylene glycol, polyvinyl-pyrroUdone, lecithin, arachis oU, or sesame oU. A typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats.
Typical transdermal formulations comprise a conventional aqueous or non- aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propeUant such as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose. Each dosage unit for oral administration contains suitably from 0.001 mg Kg to
30 mg/Kg, and preferably from 0.005 mg Kg to 15 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.001 mg/Kg to 10 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free base. The daUy dosage regimen for oral administration is suitably about 0.001 mg/Kg to 120 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free base. The daUy dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, for example about 0.005 mg/Kg to 10 mg/Kg, of a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof calculated as the free base. The active ingredient may be administered as required for example from 1 to 8 times a day or by infusion. The compositions of the invention are bronchodilators and are useful in chronic reversible obstructive lung disease for example asthma and bronchitis. In addition some of the compositions of the present invention have anti- aUergic activity and are useful in combating allergic diseases such as aUergic asthma, aUergic rhinitis, urticaria and irritable bowel syndrome. The compositions of the present invention also have vasodilator activity and are of use in the treatment of angina, hypertension and congestive heart failure. Such conditions can be treated by administration oraUy, topically, rectally, parenteraUy or by inhalation.
For administration by inhalation dosages are controUed by a valve, are administered as required and for an adult are conveniently in the range 0.1-5.0 mg of a compound of the formula (1) or a pharmaceuticaUy acceptable salt thereof.
The compounds of this invention may be co-administered with other pharmaceuticaUy active compounds, for example in combination, concurrently or sequentiaUy. Conveniently the compounds of this invention and the other active compound or compounds are formulated in a pharmaceutical composition. Examples of compounds which may be included in pharmaceutical compositions with the compounds of the formula (1) are bronchodilators such as sympathomimetic amines for example isoprenaline, isoetharine, sulbutamol, phenylephrine and ephedrine or xanthine derivatives for example theophylline and aminophyUine, anti-aUergic agents for example disodium cromoglycate, histamine Hj-antagonists, vasodilators for example hydralazine, angiotensin converting enzyme inhibitors for example captopril, anti-anginal agents for example isosorbide nitrate, glyceryl trinitrate and pentaerythritol tetranitrate, anti-arrhythmic agents for example quinidine, procainamide and Ugnocaine, calcium antagonists for example verapamil and nifedipine, diuretics such as thiazides and related compounds for example bendrofluazide, chlorothiazide, chlorothaUdone, hydrochlorothiazide, and other diuretics for example frusemide and triamterene, and sedatives for example nitrazepam, flurazepam and diazepam.
In another aspect the present invention provides a process for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of the formula (2) :
Figure imgf000007_0001
Formula (2)
with a compound of the formula (3)
Figure imgf000007_0002
Formula (3)
wherein Ar, X and R^ are as hereinbefore defined and L* is a leaving group, and thereafter optionaUy forming a pharmaceuticaUy acceptable salt thereof.
Suitably I-.* is Cι_5alkoxy, halo or Cι_6alkylthio, for examples methoxy, ethoxy, propoxy or n-butoxy. The reaction may be performed in the absence of a solvent or in a solvent such as a Cι_4alkanol (e.g. methanol or ethanol), acetonitrile or pyridine at ambient or elevated temperature such as 30 to 160°C, conveniently at reflux temperature when in the presence of a solvent.
Compounds of the formula (2) are known or may be prepared by standard methods. For example a compound of the formula (2) may be prepared by reacting in the presence of a paUadium catalyst a compound of the formula (4) with a compound of the formula (5) :
Figure imgf000008_0001
Formula (4) Formula (5) wherein one of I-.2 and L.3 is B(OH)2 and the other is a suitable leaving group, Y is amino or a precursor thereof, Arl is a group Ar as hereinbefore defined or a precursor thereof and X is as hereinbefore defined, and thereafter if necessary :
• converting a group Y to amino • converting a group Ar to Ar.
A suitable leaving group for ] or 1? is halo, preferably bromo or trifluoromethanesulphonate. Preferably l_? is B(OH)2- Suitably the reaction of a compound of the formula (4) with a compound of the formula (5) is performed in the presence of a base such as triethylamine, barium hydroxide, sodium carbonate or sodium bicarbonate, and when L-2 or l > is trifluoromethanesulphonate in the presence of Uthium chloride, in a solvent such as dimethoxyethane, tetrahydrofuran, benzene, ethanol, water or mixtures thereof, at elevated temperature (e.g. 30-150°C) preferably at the reflux temperature of the reaction mixture.
An example of a precursor of an amino group is a nitro group which can be reduced to an amino group in conventional manner, e.g. by catalytic hydrogenation. An alternative precursor is a protected amino group such as phthalamido which can be deprotected in conventional manner.
An example of a precursor of the group Ar is when Ar is substituted by an optionaUy substituted benzyloxy group such as 4-methoxybenzyloxy which can be converted to Ar substituted by hydroxy in conventional manner, e.g. by catalytic hydrogenation.
Compounds of the formula (3) are known or can be prepared by standard methods (e.g. as described in UK patent 1563090).
Compounds of the formulae (4) and (5) are known or may be prepared by standard methods.
Pharmaceutically acceptable acid addition salts of the compounds of the formula (1) may be prepared from the corresponding base of the compounds of the formula (1) in conventional manner. For example the base may be reacted with an acid in a Cμ4alkanol, or an ion-exchange resin may be used. The salts of the compounds of the formula (1) may be inter converted using ion-exchange resins. Non-pharmaceuticaUy acceptable salts are therefore of use as they can be converted to pharmaceuticaUy acceptable salts. Pharmaceutically acceptable base addition salts of the compounds of the formula (1) may be prepared by standard methods, for example by reacting a solution of the compound of the formula (1) with a solution of the base.
The foUowing biological test methods, data and Examples serve to illustrate this invention.
Bronchodilatation - In vivo
Male guinea-pigs of the Dunkin Hartley strain (500 - 600g) are anaesthetised with Sagatal (pentobarbital sodium) (60 mg/kg). Airway resistance is measured using a modification of the classical Konzett-Rossler technique (J. Pharm. Methods, 12.. 309-315, 1985). U46619 (9,1 l-methaneoepoxy-PGH2) is infused i.v. at a rate of 2.5 nmol/min, this produced a steady state of bronchoconstriction (approximately 120% increase from basal airway resistance). The compound under test is administered by i.v. bolus injection, and the subsequent peak inhibition of bronchoconstriction is recorded. The dose of compound required to reduce the U46619-induced broncho¬ constriction by 50% is given as the BD50.
Anti-allergic activity
Male Duncan Hartley guinea-pigs (250-300 g) are sensitised to ovalbumen by i.p. injection of 2 ml of 50 mg.ml"! i.p. and 0.2 ml s.c. Three weeks later they are anaesthetised with 60 mg.kg'l sodium pentabarbitone. The trachea is cannulated and the animal respires at a rate of 40 breaths per minute and at an initial tracheal inflation pressure of 16 mmHg. Tracheal inflation pressure is measured by a transducer connected to a side arm of the respiration circuit The carotid artery is cannulated for the measurement of blood pressure and the signal is used to trigger an instantaneous rate meter. A jugular vein is cannulated for the administration of drug and aUergen. After surgery the animals are aUowed to stabilise and the drug is administered i.v. as a bolus. FoUowing this, ovalbumen lmg.kg"! is injected i.v. as the antigen chaUenge either 2, 15 or 30 minutes foUowing drug treatment and the peak bronchoconstrictor response recorded. For the control group ovalbumen only is given. One ovalbumen chaUenge per guinea-pig is used and n = 6 for each time point. The percentage increase in tracheal inflation pressure is calculated.
Phosphodiesterase activity
The activity of the compounds of the present invention as inhibitors of a calmodulin insensitive cycUc GMP phosphodiesterase is measured using the procedure described in European Patent Application No.293063. The concentration of compound which inhibits the enzyme by 50% is given as the IC50 (μM). The compounds of Examples 2, 5 to 11, 13 to 16, 18, 20 and 23 had IC50 values in the range 6 to 110 μM.
Inhibition of Spontaneous Contraction in Guinea-Pig Colon
Segments of isolated guinea-pig colon (2 cm) are suspended under 2 g tension in standard organ baths containing Krebs solution. The tissues are connected at the free end to isometric transducers which allow recording and display of developed tension on chart recorders. On-line computer capture and analysis are used to quantify the effects of test compounds on spontaneous contractions. Inhibitory responses are calculated as % maximum inhibition of spontaneous contraction distance over 3 consecutive pre and post dose 2 minute readings. The concentration of compound which causes 50% inhibition of the spontaneous contraction is given as the EC50 (μM).
Example 1 3-Amino-4-[4-(3-pyridyl)]anilino-3-cycIobutene-l-2-dione A solution of 3-(4-aminophenyl)pyridine (0.51 g) and 3-amino-4-ethoxy-3-cyclobutene- 1,2-dione (0.42 g) in pyridine (2 ml) was stirred at 80° for 20 hours. The cool mixture was treated with water (15 ml) and the soUd filtered off and washed with water and hot methanol. RecrystaUation from dimethylformamide gave 0.33 g of the title compound, mp 322-4°C dec.
Example 2
3-Amino-4-[3-(4-imidazolyl)aniIino]-3-cyclobutene-l 2-dione
In a manner similar to that of Example 1, 4-(3-aminophenyl)imidazole (0.48 g) and 3- amino-4-ethoxy-3-cyclobutene-l,2-dione (0.42 g) gave 0.40 g of the title compound, mp darkens ca. 300°C (from dimethylformamide/water).
Example 3
3-Methylaπύno-4-[3-(5-methyl-4-imidazolyI)anilino]-3-cyclobutene-l,2-dione
In a manner similar to that of Example 1, 4-(3-ammophenyl)-5-methylimidazole (0.43 g) and 3-ethoxy-4-methylamino-3-cyclobutene-l,2-dione (0.39 g) gave 0.36 g of the title compound, mp >330°C (from dimethylformamide). Example 4
3-Dimethylamino-4-[3-(5-methyl-4-imidazolyl)aniIino]-3-cyclobutene-l,2-dione
In a manner similar to that of Example 1, 4-(3-aminophenyl)-5-methyl-imidazole (0.57 g) and 3-dimethylamino-4-ethoxy-3-cyclobutene-l,2-dione (0.56 g) gave 0.34 g of the title compound, mp 290-292°C (from methanol).
Example 5
3-Amino-4-[3-(3-methyI-4-pyridyl)aniIino]-3-cyclobutene-l 2-dione
In a manner similar to that of Example 1, 4-(3-aminophenyl)-2-methylpyridine (0.55 g) and 3-amino-4-ethoxy-3-cyclobutene-l ,2-dione (0.42 g) gave 0.28 g of the title compound, mp 205-208°C (from dimemylformamide).
Example 6
3-Amino-4-[3-(2-oxazolyl)anilino]-3-cyclobutene-l,2-dione In a manner similar to that of Example 1, 2-(3-aminophenyl)oxazole (0.50 g) and 3- amino-4-ethoxy-3-cyclobutene-l,2-dione (0.44 g) gave 0.56 g of the title compound, mp 312-314°C (from dimethylformamide).
Example 7 3-Amino-4-[3-(4-pyridyI)anilino]-3-cyclobutene-l-2-dione
(a) A stirred mixture of 3-nitrophenylboronic acid (2.00 g), 4-bromopyridine hydrochloride (1.56 g), bis(diphenylphosphino)butanepaUadium(II) chloride (0.48 g), sodium bicarbonate (2.69 g), water (30 ml) and 1,2-dimethoxyethane (100 ml) was heated under reflux for 3 hours. The cool mixture was added to water (300 ml) and extracted with chloroform (3 x 150 ml), and the combined organic extracts washed with water and brine, dried (MgSO4), charcoaled and filtered. The solvent was evaporated to give a residue which was purified by flash chromatography (siUca, ether) to give 1.19 g of 4-(3- nitrophenyl)pyridine, mp 109-110.5°C (from acetone hexane).
(b) A solution of the above nitre compound (1.18 g) in ethanol (30 ml) was shaken with 10% paUadium on carbon (0.2 g) under hydrogen (50 psi) for 2.5 hours.
Evaporation of the filtered solution gave a soUd residue which was recrystaUised from ethanol/40-60° Pet ether to give 0.81 g of 4-(3-aminophenyl)pyridine, mp 167.5-168°C.
(c) In a manner similar to that of Example 1 , the above amino compound (0.50 g) and 3-amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.50 g) gave 0.50 g of the title compound, mp 297-300°C dec. (from dimethylformamide). Example 8 3-Aιnino-4-[3-(3-pyridyl)anilino]-3-cyclobutene-l,2-dione
(a) In a manner similar to that of Example 7(a), 3-nitrophenylboronic acid (2.00 g) and 3-bromopyridine (1.26 g) gave 1.22 g of 3-(3-nitrophenyl)pyridine, mp 98.5- 101°C (from acetone/hexane).
(b) A stirred mixture of the above nitro compound (1.22 g), stannous chloride dihydrate (6.5 g), cone, hydrochloric acid (6.5 ml) and ethanol (12.5 ml) was heated under reflux for 3.5 hours. Most of the ethanol was evaporated under reduced pressure and the residue made alkaline with 40% sodium hydroxide solution. The mixture was extracted with toluene (3 x 20 ml) and the combined organic extracts washed with water, dried (MgSO4) and evaporated to give a residue which was recrystaUised from chloroform/40-60o Pet ether to give 0.92 g of 3-(3-aminophenyl)pyridine, mp 75-76°C.
(c) In a manner simUar to that of Example 1, the above amino compound (0.51 g) and 3-amino-4-ethoxy-3-cyclobutene-l,2-dione (0.42 g) gave 0.45 g of the title compound, mp 256-258°C (from methanol).
Example 9 3-Amino-4-[3-(2-pyridyl)anilino]-3-cyclobutene-l,2-dione (a) In a manner simUar to that of Example 7(a), 3-nitrophenylboronic acid
(1.45 g), 2-bromopyridine (1.26 g) and tetrakis(triphenylphosphine)paUadium(0) (0.50 g) gave 0.92 g of 2-(3-nitrophenyl)pyridine, mp 71.5-73°C (from ethanol).
(b) In a manner simUar to that of Example 7(b), the above nitro compound (0.92 g) gave 2-(3-aminophenyl)pyridine (0.50 g) as a colourless oU. (c) In a manner simUar to that of Example 1, the above amino compound
(0.50 g) and 3-amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.50 g) gave 0.50 g of the title compound, mp 300-303°C dec. (from dimethylformamide/water).
Example 10 3-Amino-4-[3-(2-thienyl)anilino]-3-cyclobutene-ly2-dione
(a) In a manner simUar to that of Example 7(a), 3-nitrophenylboronic acid (2.00 g) and 2-bromothiophene (1.30 g) gave 0.69 g of 2-(3-nitrophenyl)thiophene, mp 70-72°C (from ether).
(b) In a manner simUar to that of Example 8(b), the above nitro compound (0.69 g) and stannous chloride dihydrate (3.6 g) gave 0.43 g of 2-(3-aminophenyl)- thiophene, mp 30.5-32°C. (c) In a manner similar to that of Example 1, the above amino compound
(0.42 g) and 3-amino-4-ethoxy-3-cyclobutene-l,2-dione (0.34 g) gave 0.35 g of the title compound, mp 297-299°C dec. (from dimethylforrnamide/water).
Example 11
3-Amino-4-[3-(3-thienyl)anilino]-3-cyclobutene-l,2-dione
(a) In a manner simUar to that of Example 7(a), 3-nitrophenylboronic acid
(1.45 g), 3-bromothiophene (1.30 g) and tetrakis(triphenylphosphine)paUadium(0) (0.50 g) gave 1.46 g of 3-(3-nitrophenyl)thiophene, mp 70.5-72.5°C (from ether hexane). (b) In a manner simUar to that of Example 8(b), the above nitro compound
(0.72 g) and stannous chloride dihydrate (3.75 g) gave 0.38 g of 3-(3- aminophenyl)thiophene, mp 86-88°C.
(c) In a manner similar to that of Example 1, the above amino compound (0.37 g) and 3-amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.36 g) gave 0.37 g of the title compound, mp 304-307°C dec. (from dmethylformamide/water).
Example 12 3-Amino-4-[3-(2-thianaphthenyl)anilino]-3-cyclobutene-lf2-dione
(a) In a manner simUar to that of Example 7(a), 3-nitrophenylboronic acid (2.20 g), 2-bromothianaphthene (2.81 g) and tetrakis(triphenylphosphine)paUadium(0)
(0.25 g) gave 1.19 g of 2-(3-nitrophenyl)thianaphthene, mp 158-159°C (from acetone).
(b) In a manner simUar to that of Example 8(b), the above nitro compound (1.18 g) and stannous chloride dihydrate (5.0 g) gave 0.45 g of 2-(3- aminophenyl)thianaphthene, mp 146-147°C. (c) In a manner simUar to that of Example 1, the above amino compound
(0.44 g) and 3- amino-4-ethoxy-3-cyclobutene-l,2-dione (0.33 g) gave 0.37 g of the title compound, mp 318-321°C dec. (from dimethylformamide/water).
Example 13 3-Amino-4-[3-(5-pyrimidyl)anilino]-3-cyclobutene-l,2-dione
(a) In a manner similar to that of Example 7(a), 3-nitrophenylboronic acid (2.00 g) and 5-bromopyrimidine (1.27 g) gave 1.16 g of 5-(3-nitrophenyl)pyrimidine, mp 159-160.5°C (from acetone).
(b) In a manner simUar to that of Example 7(b), the above nitro compound (0.91 g) gave 0.65 g of 5-(3-aminophenyl)pyrimidine, mp 165-167.5°C (from acetone/hexane). (c) In a manner similar to that of Example 1, the above amino compound
(0.51 g) and 3-amino-4-ethoxy-3-cyclobutene-l,2-dione (0.42 g) gave 0.51 g of the tide compound, mp 288-290°C dec. (from dimethylformamide/water).
Example 14
3-Amino-4-[3-(2-benzoxazoyl)aniIino]-3-cyclobutene-l-2-dione
In a manner simUar to that of Example 1, 2-(3-aminophenyl)benzoxazole (0.49 g) and 3- amino-4-ethoxy-3-cyclobutene-l,2-dione (0.33 g) gave 0.25 g of the tide compound, mp 330-332°C dec. (from dimeΛytformamide/water).
Example 15
3-Amino-4-[3-(2-benzimidazolyl)aniIino]-3-cyclobutene-l,2-dione
In a manner simUar to tiiat of Example 1, 2-(3-aminophenyl)benzimidazole (0.52 g) and 3- amino-4-ethoxy-3-cyclobutene-l,2-dione (0.36 g) gave 0.35 g of the tide compound, mp >320°C (from dimethylformamide/water).
Example 16
3-Amino-4-[3-(2-indolyl)aniIino]-3-cyclobutene-l,2-dione
In a manner simUar to diat of Example 1, 2-(3-aminophenyl)indole (0.48 g) and 3-amino- 4-ethoxy-3-cyclobutene-l ,2-dione (0.33 g) gave 0.22 g of die tide compound, mp ca, 335° C dec. (from dimemylformamide/water).
Example 17
3-Amino-4-(3-phenyl)anilino-3-cyclobutene-l,2-dione (a) In a manner similar to that of Example 7(b), 3-nitrobiphenyl (2.48 g) gave 1.77 g of 3-aminobiphenyl, mp 27.5-28.5°C.
(b) In a manner simUar to that of Example 1, 3-aminobiphenyl (0.51 g) and 3-am o-4-ethoxy-3-cyclobutene-l ,2-dione (0.42 g) gave 0.33 g of the tide compound, mp 300-301°C (from dimethylformamide/water).
Example 18
3-Amino-4-[3-(2-hydroxyphenyI)anilino]-3-cycIobutene-l-2-dione
(a) A stirred mixture of 2-bromophenol (5.19 g), 4-methoxybenzyl chloride (4.70 g), potassium carbonate (4.15 g) and acetone (30 ml) was heated under reflux for 8 hours. The cool mixture was evajxwated under reduced pressure and die residue was mixed witii water (60 ml) and etiier (60 ml) and shaken. The aqueous layer was extracted with ether (2 x 60 ml) and die combined extracts washed witii 2M sodium hydroxide solution (20 ml) and water (20 ml), dried (MgSO4) and evaporated to give a soUd residue which was recrystaUised from ethanol to give 6.18 g of l-bromo-2-(4-methoxybenzyloxy)- benzene, mp 87-90°C.
(b) In a manner simUar to tiiat of Example 7(a), 3-nitrophenylboronic acid (1.09 g), l-bromo-2-(4-methoxybenzyloxy)benzene (1.76 g) and tetrakis(triphenyl- phosphine)palladium(O) (0,20 g) gave 1.34 g of 2-(4-methoxybenzyloxy)-3'-nitrobiphenyl, mp 99.5- 100.5°C (from acetone/ether).
(c) In a manner similar to that of Example 7(b), the above nitro compound (0.86 g) gave 0.29 g of 2-hydroxy-3'-aminobiphenyl, mp 158-161°C.
N.B.: It is possible to terminate tiiis reaction after adsorption of 3 moles of hydrogen to give 2-(4-methoxybenzyloxy)-3'-aminobiphenyl, mp 68-70°C (from ether/hexane). (d) In a manner simUar to mat of Example 1, 2-hydroxy-3'-aminobiphenyl
(0.28 g) and 3-amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.26 g) gave 0.19 g of the tide compound, mp 294-297°C dec. (from dimethylformamide/water).
Example 19 3-Amino-4-[3-(2-methoxyphenyI)anilino]-3-cyclobutene-l,2-dione
(a) In a manner simUar to mat of Example 7(a), 3-nitrophenylboronic acid, (1.45 g), 2-bromoanisole (1.50 g) and tetrakis(triphenylphosphine)paUadium(0) (0.25 g) gave 0.39 g of 2-methoxy-3'-nitrobiphenyl, mp 67-8°C.
(b) In a manner simUar to that of Example 7(b), the above nitro compound (0.39 g) gave 174 mg of 2-metiιoxy-3'-aminobiphenyl as an oU.
(c) In a manner similar to mat of Example 1, d e above amino compound (174 mg) and 3-amino-4-n-butoxy-3-cyclobutene-l^-dione (148 mg) gave 146 mg of the tide compound, mp 294-296°C (from dimediylformamide/water).
Example 20
3-Amino-4-[3-(3-hydroxy-2-pyridyl)anilino]-3-cyclobutene-l,2-dione
(a) A stirred mixture of 2,6-dibromopyridine (3.55 g), benzyl alcohol
(1.63 g), potassium hydroxide (1.68 g), 18-Crown-6 (0.20 g) and toluene (25 ml) was heated under reflux for 30 minutes. The cool solution was washed widi water and brine, dried (MgSO4) and evaporated to give an oU which was vacuum-distiUed (Kugelrohr) to give 3.85 g of 2-benzyloxy-6-bromopyridine, bp 220-225°C / 1.0 mm. (b) In a manner simUar to that of Example 7(a), 3-nitrophenylboronic acid
(1.09 g), 2-benzyloxy-6-bromopyridine (1.58 g) and tetrakis(triphenylphosphine)- paUadium(O) (0.40 g) gave 0.95 g of 2-benzyloxy-6-(3-nitrophenyl)pyridine, mp 82.5-83.5 °C (from ether). (c) In a manner simUar to that of Example 7(b), the above nitro compound
(0.94 g) gave 0.37 g of 2-(3-aminophenyl)-6-hydroxypyridine, mp 237-239°C (from methanol).
(d) In a manner similar to that of Example 1 , die above amino compound (0.36 g) and 3- amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.32 g) gave 0.46 g of the tide compound, mp 320-322°C dec. (from dimethylformamide).
Example 21 3-Amino-4-[3-(2-imidazolyl)anilino]-3-cyclobutene-l,2-dione
(a) A stirred solution of methyl 3-nitrobenzimidate (7.57 g) and aminoacetaldehyde dimethylacetal (5.57 g) in methanol (20 ml) was heated under reflux for 24 hours. The cool solution was eva*porated and die residue treated witii water (9.5 ml) and cone, hydrochloric acid (21 ml). The mixture was heated (steam batii) for 15 minutes and evaporated under reduced pressure. Water (50 ml) was added to the residue and the insoluble soUd filtered and washed with water. The filtrate was neutraUzed with -potassium carbonate solution and die precipitated soUd filtered and washed witii water. The combined soUds were charcoaled and recrystaUised from ethanol to give 3.87 g of 2-(3- nitrophenyl)imidazole, mp 193-194.5°C.
(b) In a manner simUar to that of Example 8(b), die above nitro compound (0.72 g) and stannous chloride dihydrate (4.25 g) gave 0.39 g of 2-(3-aminophenyl)- imidazole, mp 134-135.5°C.
(c) In a manner simUar to mat of Example 1, the above amino compound (0.38 g) and 3-amino-4-n-butoxy-3-cyclobutene-l,2-dione (0.40 g) gave 0.34 g of the tide compound, mp >340°C (from dimediylformamide).
Example 22
3-Amino-4-[6-(4-pyridyl)-2-pyridylamino]-3-cyclobutene-l^-dione
A stirred solution of 2-amino-6-(4-pyridyl)pyridine (0.34 g) and 3-amino-4-n-butoxy-3- cyclobutene-1 ,2-dione (0.34 g) in pyridine (2 ml) was heated under reflux for 8 hours. The cool mixture was treated with water (15 ml) and die mixture stirred for 1 hour. The soUd was filtered, washed with water, ethanol and ether, charcoaled and recrystaUised from dimethylformamide to give 73 mg of me title compound, mp >340°C. Example 23
3-[3-(4-Pyridyl)anilino]-3-cyclobutene-l,2-dione
A solution of 4-(3-aminophenyl)pyridine (0.81 g) and 3-n-butoxy-3-cyclobutene-l ,2-dione (0.73 g) in ethanol (20 ml) was stirred at ambient temperature for 15 hours. The resultant precipitated soUd was washed witii methanol and edier and recrystaUised from dimediylformamide to give 0.91 g of the tide compound, mp 252-255.5°C.
Example 24 Pharmaceutical compositions for oral administration are prepared by combining the foUowing :
% w/w 3-Amino-4-[4-(3-pyridyl)]anUino- 3-cyclobutene- 1,2-dione 0.5 3.0 7.14
2% w/w Soya lecithin in soya bean oU 90.45 88.2 84.41
Hydrogenated vegetable shortening and beeswax 9.05 8.8 8.45 The formulations are then filled into individual soft gelatin capsules.
Example 25
A pharmaceutical composition for parenteral administration is prepared by dissolving die title compound of Example 2 (0.02 g) in polyethylene glycol 300 (25 ml) with heating. This solution is then dUuted with water for injections Ph. Eur. (to 100 ml). The solution is tiien sterilised by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Claims

Claims
1. A compound of the formula ( 1 )
Figure imgf000018_0001
Formula (1)
or a pharmaceuticaUy acceptable salt thereof, wherein Ar is an optionaUy substimted aryl or heteroaryl ring selected from phenyl, naphtiiyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, imidazolyl, thienyl, oxazolyl, benzimidazolyl, benzoxazolyl, indolyl or thianaphthenyl, X is CH or N;
R° is NR!R2 or hydrogen; and R! and R2 are independendy hydrogen or Cχ_5alkyl.
2. A compound according to claim 1 wherein Ar is phenyl.
3. A compound according to claim 1 wherein Ar is 2- ,3- or 4-pyridyl, 5- pyrimidyl, 2- or 4-imidazolyl, 2- or 3-thienyl, 2-oxazolyl, 2-benzimidazolyl, 2- benzoxazolyl, 2-indolyl or 2-dιianaphthenyl.
4. A compound acording to any one of claims 1 to 3 wherein Ar is unsubstituted or substituted by at least one group selected from C1.5al.kyl, Cι_5alkoxy or hydroxy.
5. A compound according to any one of claims 1 to 4 wherein Ar is positioned ortho- or meta- to X.
6. A compound according to any one of claims 1 to 5 wherein X is CH.
7. A compound according to any one of claims 1 to 6 wherein R^ is
NRJR2.
8. A compound according to claim 7 wherein R* is hydrogen and R2 is hydrogen or Cι_5alkyl.
9. A compound according to claim 1 selected from : 3-amino-4-[4-(3-pyridyl)]anUino-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(4-imidazolyl)anUino]-3-cyclobutene- 1 ,2-dione, 3-methylamino-4- [3-(5-methyl-4-imidazolyl)anUino] -3-cyclobutene- 1 ,2-diorie, 3-dimethylamino-4- [3-(5-methyl-4-imidazolyl)aniUno] -3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(3-medιyl-4-pyridyl)anilino]-3-cyclobutene-l,2-dione, 3-ammc-4-[3-(2-oxa2»lyl)anilino]-3-cyclobutene-l,2-dione, 3-amino-4-[3-(4-pyridyl)aniUno]-3-cyclobutene-l,2-dione, 3-amino-4-[3-(3-pyridyl)aniUno]-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(2-pyridyl)aniUno]-3-cyclobutene-l,2-dione, 3-amino-4-[3-(2-thienyl)anilino]-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(3-thienyl)anUino]-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(2-thianaphthenyl)anilino]-3-cyclobutene- 1 ,2-dione, 3-ammo-4-[3-(5-pyrimidyl)anilino]-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(2-benzoxazoyl)anUino]-3-cyclobutene-l,2-dione, 3-amino-4-[3-(2-benzimidazolyl)aniUno] -3-cyclobutene- 1 ,2-dione, 3-amino-4- [3-(2-indolyl)aniUno] -3-cyclobutene- 1 ,2-dione, 3-ammo-4-(3-phenyl)anilino-3-cyclobutene- 1 ,2-dione, 3-amino-4-[3-(2-hydroxyphenyl)anilino]-3-cyclobutene-l,2-dione, 3-amino-4-[3-(2-methoxyphenyl)anUino]-3-cyclobutene-l,2-dione, 3-ammo-4-[3-(3-hydroxy-2-pyridyl)anUino]-3-cyclobutene-l,2-dione, 3-am o-4-[3-(2-imidazolyl)anilino]-3-cyclobutene-l,2-dione, 3-ammo-4-[6-(4-pyridyl)-2-pyridylamino]-3-cyclobutene-l^-dione, or 3-[3-(4-pyridyl)anilino]-3-cyclobutene-l,2-dione, or a pharmaceuticaUy acceptable salt thereof.
10. A compound according to any one of claims 1 to 9 for use as a medicament
11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
12. A process for the preparation of a compound of the formula (1) as defined in claim 1 or a pharmaceuticaUy acceptable salt thereof, which process comprises reacting a compound of the formula (2) :
Figure imgf000020_0001
Formula (2)
with a compound of the formula (3) :
Figure imgf000020_0002
Formula (3)
wherein Ar, X and R^ arc as hereinbefore defined and L* is a leaving group, and thereafter optionaUy forming a pharmaceuticaUy acceptable salt thereof.
13. The use of a compound according to any one of claims 1 to 9 in the manufacture of a medicament for inhibiting a calmodulin insensitive cycUc GMP phosphodiesterase.
PCT/EP1994/001921 1993-06-14 1994-06-07 AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS WO1994029277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9312210.9 1993-06-14
GB939312210A GB9312210D0 (en) 1993-06-14 1993-06-14 Chemical compounds

Publications (1)

Publication Number Publication Date
WO1994029277A1 true WO1994029277A1 (en) 1994-12-22

Family

ID=10737123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/001921 WO1994029277A1 (en) 1993-06-14 1994-06-07 AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS

Country Status (2)

Country Link
GB (1) GB9312210D0 (en)
WO (1) WO1994029277A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014300A1 (en) * 1994-11-04 1996-05-17 American Home Products Corporation N-aryl and n-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities
WO1996016644A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
EP0994100A1 (en) * 1997-06-24 2000-04-19 Nikken Chemicals Company, Limited 3-anilino-2-cycloalkenone derivates
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6100270A (en) * 1994-11-26 2000-08-08 Pfizer Inc. Bicyclic heterocyclic compounds for the treatment of impotence
WO2000051973A1 (en) * 1999-03-04 2000-09-08 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives, preparation method and therapeutic use
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
WO2000063170A1 (en) * 1999-04-20 2000-10-26 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
US6177471B1 (en) 1999-01-29 2001-01-23 Cell Pathways, Inc. Method for treating patients with acne by administering a CGMP-specific PDE inhibitor
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6211220B1 (en) * 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US6740654B2 (en) * 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
JP2004532846A (en) * 2001-04-16 2004-10-28 シェーリング　コーポレイション 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US6903131B2 (en) 2001-10-12 2005-06-07 Schering Corporation 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
JP2005534684A (en) * 2002-07-30 2005-11-17 シェーリング　コーポレイション 3,4-Disubstituted cyclobutene-1,2-diones as CXC chemokine receptor ligands
US7115647B2 (en) 1998-01-14 2006-10-03 Osi Pharmaceuticals, Inc. Method of inhibiting neoplastic cells with indole derivatives
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR100710991B1 (en) * 2001-07-27 2007-04-24 주식회사유한양행 3-Cyclobutene-1,2-dione derivatives and processes for the preparation thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7338968B2 (en) 2003-12-19 2008-03-04 Schering Corporation Thiadiazoles AS CXC- and CC- chemokine receptor ligands
FR2918665A1 (en) * 2007-07-13 2009-01-16 Sod Conseils Rech Applic TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES AS CDC25 PHOSPHATASE INHIBITORS
US7671212B2 (en) 2003-12-22 2010-03-02 Schering Corporation Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
US7691856B2 (en) 2002-10-09 2010-04-06 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
US7718678B2 (en) 2005-06-29 2010-05-18 Schering Corporation Di-substituted oxadiazoles as CXC-chemokine receptor ligands
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7897606B2 (en) 2005-06-29 2011-03-01 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands
US7960433B2 (en) 2002-03-18 2011-06-14 Schering Corporation Treatment of chemokine mediated diseases
US8273876B2 (en) 2002-07-16 2012-09-25 Bayer Intellectual Property Gmbh Medicaments containing vardenafil hydrochloride trihydrate
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395328A2 (en) * 1989-04-26 1990-10-31 Smith Kline & French Laboratories Limited Penylpyrimidone derivates and their use as therapeutic agents
EP0400799A1 (en) * 1989-04-26 1990-12-05 Smith Kline & French Laboratories Limited Phenylpyrimidone derivatives
EP0428268A2 (en) * 1989-10-13 1991-05-22 Smith Kline & French Laboratories Limited Pharmaceutical phenylpyridone derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395328A2 (en) * 1989-04-26 1990-10-31 Smith Kline & French Laboratories Limited Penylpyrimidone derivates and their use as therapeutic agents
EP0400799A1 (en) * 1989-04-26 1990-12-05 Smith Kline & French Laboratories Limited Phenylpyrimidone derivatives
EP0428268A2 (en) * 1989-10-13 1991-05-22 Smith Kline & French Laboratories Limited Pharmaceutical phenylpyridone derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, no. 7, 15 February 1988, Columbus, Ohio, US; abstract no. 48712j, DAVIS, A. ET AL.: "Strategic approaches to drug design. II. Modeling studies on phosphodiesterase substrates and inhibitors." *
J. COMPUT.-AIDED MOL. DES. 1987,1(2),97-119 *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014300A1 (en) * 1994-11-04 1996-05-17 American Home Products Corporation N-aryl and n-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities
WO1996016644A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION
US6534511B1 (en) 1994-11-26 2003-03-18 Pfizer Inc. Bicyclic heterocyclic compounds for the treatment of impotence
US6300335B1 (en) 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
US6100270A (en) * 1994-11-26 2000-08-08 Pfizer Inc. Bicyclic heterocyclic compounds for the treatment of impotence
EP0994100A4 (en) * 1997-06-24 2003-05-02 Nikken Chemicals Co Ltd 3-anilino-2-cycloalkenone derivates
EP0994100A1 (en) * 1997-06-24 2000-04-19 Nikken Chemicals Company, Limited 3-anilino-2-cycloalkenone derivates
US7122540B2 (en) 1997-11-12 2006-10-17 Bayer Healthcare Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7696206B2 (en) 1997-11-12 2010-04-13 Bayer Schering Pharma Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6890922B2 (en) 1997-11-12 2005-05-10 Bayer Healthcare Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6566360B1 (en) 1997-11-12 2003-05-20 Bayer Aktiengesellschaft 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors
US7314871B2 (en) 1997-11-12 2008-01-01 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension
US7704999B2 (en) 1997-11-12 2010-04-27 Bayer Schering Pharma Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7115647B2 (en) 1998-01-14 2006-10-03 Osi Pharmaceuticals, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6211220B1 (en) * 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6177471B1 (en) 1999-01-29 2001-01-23 Cell Pathways, Inc. Method for treating patients with acne by administering a CGMP-specific PDE inhibitor
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
WO2000051973A1 (en) * 1999-03-04 2000-09-08 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives, preparation method and therapeutic use
FR2790472A1 (en) * 1999-03-04 2000-09-08 Synthelabo CYCLOBUTENE-3, 4-DIONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
WO2000063170A1 (en) * 1999-04-20 2000-10-26 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
FR2792635A1 (en) * 1999-04-20 2000-10-27 Synthelabo 2-Amino-cyclobutene-3,4-dione cyclohexane carboxamide derivatives are phosphodiesterase inhibitors useful for treating e.g. incontinence, dysmenorrhea, premature labor, sexual dysfunction, angina and asthma
US6740654B2 (en) * 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US7964646B2 (en) 2001-04-16 2011-06-21 Schering Corporation 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2004532846A (en) * 2001-04-16 2004-10-28 シェーリング　コーポレイション 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7947720B2 (en) 2001-04-16 2011-05-24 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR100710991B1 (en) * 2001-07-27 2007-04-24 주식회사유한양행 3-Cyclobutene-1,2-dione derivatives and processes for the preparation thereof
US6903131B2 (en) 2001-10-12 2005-06-07 Schering Corporation 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US7960433B2 (en) 2002-03-18 2011-06-14 Schering Corporation Treatment of chemokine mediated diseases
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US9018243B2 (en) 2002-03-20 2015-04-28 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US11260046B2 (en) 2002-03-20 2022-03-01 Amgen Inc. (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US11040024B2 (en) 2002-03-20 2021-06-22 Amgen Inc. Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7507759B2 (en) 2002-03-20 2009-03-24 Celgene Corporation Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione
US7659303B2 (en) 2002-03-20 2010-02-09 Celgene Corporation Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione
US7659302B2 (en) 2002-03-20 2010-02-09 Celgene Corporation Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
US10610516B2 (en) 2002-03-20 2020-04-07 Amgen Inc. Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione
US10092542B2 (en) 2002-03-20 2018-10-09 Celgene Corporation Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7358272B2 (en) 2002-03-20 2008-04-15 Celgene Corporation Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
US9724330B2 (en) 2002-03-20 2017-08-08 Celgene Corporation Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US9433606B2 (en) 2002-03-20 2016-09-06 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US9283207B2 (en) 2002-03-20 2016-03-15 Celgene Corporation Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7427638B2 (en) 2002-03-20 2008-09-23 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US8802717B2 (en) 2002-03-20 2014-08-12 Celgene Corporation Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US8629173B2 (en) 2002-03-20 2014-01-14 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8093283B2 (en) 2002-03-20 2012-01-10 Celgene Corporation Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof
US8455536B2 (en) 2002-03-20 2013-06-04 Celgene Corporation Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
US8841446B2 (en) 2002-07-16 2014-09-23 Bayer Intellectual Property Gmbh Medicaments containing vardenafil hydrochloride trihydrate
US8273876B2 (en) 2002-07-16 2012-09-25 Bayer Intellectual Property Gmbh Medicaments containing vardenafil hydrochloride trihydrate
JP2005534684A (en) * 2002-07-30 2005-11-17 シェーリング　コーポレイション 3,4-Disubstituted cyclobutene-1,2-diones as CXC chemokine receptor ligands
US7691856B2 (en) 2002-10-09 2010-04-06 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
US7338968B2 (en) 2003-12-19 2008-03-04 Schering Corporation Thiadiazoles AS CXC- and CC- chemokine receptor ligands
US7786149B2 (en) 2003-12-19 2010-08-31 Schering Corp. Thiadiazoles as CXC- and CC- chemokine receptor ligands
US7671212B2 (en) 2003-12-22 2010-03-02 Schering Corporation Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
US7718678B2 (en) 2005-06-29 2010-05-18 Schering Corporation Di-substituted oxadiazoles as CXC-chemokine receptor ligands
US7897606B2 (en) 2005-06-29 2011-03-01 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands
JP2010533209A (en) * 2007-07-13 2010-10-21 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Triaminopyrimidine cyclobutenedione derivatives as inhibitors of CDC25 phosphatase
WO2009034258A1 (en) * 2007-07-13 2009-03-19 Ipsen Pharma S.A.S. Tri-amino-pyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors
FR2918665A1 (en) * 2007-07-13 2009-01-16 Sod Conseils Rech Applic TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES AS CDC25 PHOSPHATASE INHIBITORS
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Also Published As

Publication number Publication date
GB9312210D0 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
WO1994029277A1 (en) AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS
US5254571A (en) Chemical compounds
RU2188188C2 (en) Trisubstituted phenyl derivatives
US5073559A (en) 2-Substituted purinone having phosphodiesterase inhibitory activity
US5118686A (en) Phenylpyrimidones
CA1303037C (en) Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
KR100564902B1 (en) Novel thiourea derivatives and the pharmaceutical compositions containing the same
IE903657A1 (en) Chemical compounds
JPH04503212A (en) 4-Hydroxythiazole as a 5-lipoxygenase inhibitor
JPS62281858A (en) Piperidine derivative and analogous derivative thereof
HU180945B (en) Process for preparing pyrimidones
NZ260816A (en) N-substituted,2-substituted-2-propen(thio)amide; 4-pyrazolyl-, 4-imidazolyl-propenoic acid intermediates
WO2009158315A1 (en) Prolyl hydroxylase inhibitors
EP0347027B1 (en) Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them.
CN110357789A (en) N- substituted acrylamide derivative and its preparation and use as DHODH inhibitor
US6737429B2 (en) Pyrrole derivatives
EP0112142A2 (en) Pyridine derivatives
AU2001263874A1 (en) Pyrrole derivatives for treating aids
JPS60193991A (en) Imidazoquinazolinyloxyalkylamide derivative
HU202106B (en) Process for producing pharmaceutical compositions containing pyrazolin derivatives
EP0244201B1 (en) 3-hydroxypyridines
JPH05262761A (en) Arylalkylamine derivative
US4388317A (en) Pyrimidones having histamine H2 -antagonist activity
EP0134091B1 (en) Pyrimidone derivatives
AU2011328673B2 (en) Compound for increasing kinase active and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase